Update zur Studienlandschaft. Zirkulierende Tumorzellen beim metastasierten Mammakarzinom

Das primäre Mammakarzinom gilt schon zum Zeitpunkt der Erstdiagnose als eine potenziell systemische Erkrankung. Die kontinuierliche Streuung von isolierten Tumorzellen (ITZ) in die Blutbahn von Patientinnen mit Mammakarzinom stellt ein lang bekanntes Phänomen dar [1]. Nach der Hypothese der metastatischen Ineffizienz (metastatic inefficiency) werden die meisten dieser Zellen vom Immunsystem oder durch mechanische Scherkräfte des Blutes eliminiert [2], [3]. Eine kleine Subpopulation kann jedoch langfristig im Blut oder in sogenannten „secondary homing sites“ persistieren und gilt als Surrogatmarker der minimalen Tumorresterkrankung (minimal residual disease, MRD) und somit einer späteren Fernmetastasierung.

• Literatur

• 1 Pantel K, Braakenhoff RH. Dissecting the metastatic cascade. Nat Rev Cancer 2004; 4: 448-456
• 2 Luzzi KJ, MacDonald IC, Schmidt EE et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol 1998; 153: 865-873
• 3 Méhes G, Witt A, Kubista E et al. Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001; 159: 17-20
• 4 Braun S, Vogl FD, Naume B et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med 2005; 353: 793-802
• 5 Cristofanilli M, Budd GT, Ellis MJ et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004; 351: 781-791
• 6 Budd GT, Cristofanilli M, Ellis MJ et al. Circulating tumor cells versus imaging–predicting overall survival in metastatic breast cancer. Clin Cancer Res 2006; 12: 6403-6409
• 7 Hayes DF, Cristofanilli M, Budd GT et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res 2006; 12: 4218-4224
• 8 Giuliano M, Giordano A, Jackson S et al. Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment. Breast Cancer Res 2011; 13: R67
• 9 Fehm T, Krawczyk N, Solomayer EF et al. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 2008; 10: R76
• 10 Banys M, Krawczyk N, Becker S et al. The influence of removal of primary tumor on incidence and phenotype of circulating tumor cells in primary breast cancer. Breast Cancer Res Treat 2012; 132: 121-129
• 11 Solomayer EF, Becker S, Pergola-Becker G et al. Comparison of HER2 status between primary tumor and disseminated tumor cells in primary breast cancer patients. Breast Cancer Res Treat 2006; 98: 179-184
• 12 Krawczyk N, Banys M, Neubauer H et al. HER2 status on persistent disseminated tumor cells after adjuvant therapy may differ from initial HER2 status on primary tumor. Anticancer Res 2009; 29: 4019-4024
• 13 Alix-Panabieres C, Pantel K. Circulating tumor cells: liquid biopsy of cancer. Clin Chem 2013; 59: 110-118
• 14 Rack B, Jückstock J, Günthner-Biller M et al. Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients. Arch Gynecol Obstet 2012; 285: 485-492
• 15 Bozionellou V, Mavroudis D, Perraki M et al. Trastuzumab administration can effectively target chemotherapy-resistant cytokeratin-19 messenger RNA-positive tumor cells in the peripheral blood and bone marrow of patients with breast cancer. Clin Cancer Res 2004; 10: 8185-8194
• 16 Bernhard H, Neudorfer J, Gebhard K et al. Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer. Cancer Immunol Immunother 2008; 57: 271-280